Cargando…

Outcomes in Post Lung Transplant Patients Diagnosed with COVID 19

PURPOSE: The manifestations and complications of SARS-CoV-2 infection in solid organ transplant are poorly known. Lung Transplant group is an immunocompromised group with a shock organ of COVID-19. For this, we analyze the possible risk factors associated with an unfavorable outcome METHODS: Retrosp...

Descripción completa

Detalles Bibliográficos
Autores principales: Pêgo-Fernandes, P., Reis, F. Pola Dos, Santos, S., Fernandes, L.M., Abdalla, L.G., Aguiar, I.T., Campos, S.V., de Camargo, P. L. Bueno, Costa, A.N., Carraro, R.M., Pires, J.P., Teixeira, R.O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988623/
http://dx.doi.org/10.1016/j.healun.2022.01.1555
_version_ 1784683003526512640
author Pêgo-Fernandes, P.
Reis, F. Pola Dos
Santos, S.
Fernandes, L.M.
Abdalla, L.G.
Aguiar, I.T.
Campos, S.V.
de Camargo, P. L. Bueno
Costa, A.N.
Carraro, R.M.
Pires, J.P.
Teixeira, R.O.
author_facet Pêgo-Fernandes, P.
Reis, F. Pola Dos
Santos, S.
Fernandes, L.M.
Abdalla, L.G.
Aguiar, I.T.
Campos, S.V.
de Camargo, P. L. Bueno
Costa, A.N.
Carraro, R.M.
Pires, J.P.
Teixeira, R.O.
author_sort Pêgo-Fernandes, P.
collection PubMed
description PURPOSE: The manifestations and complications of SARS-CoV-2 infection in solid organ transplant are poorly known. Lung Transplant group is an immunocompromised group with a shock organ of COVID-19. For this, we analyze the possible risk factors associated with an unfavorable outcome METHODS: Retrospective study between the period march 2020 until june 2021. We analysed the database of Lung Transplant and medical records. It included all patients with a confirmed diagnosis of COVID-19 in our cohort with RT-PCR SARS-COV-2 or rapid test and chest computed tomography compatible. We analyzed demographic features and outcomes: sex; type of transplant (unilateral or bilateral); presence of chronic graft dysfunction; transplant time; confirmed prior rejections; history of SAH and/or DM; nosocomial transmission infection; report of fever and/or dyspnea; need for hospitalization and/or ICU; use of an O2 nasal catheter and/or mechanical ventilation; need of dyalisis; associated bronchopneumonia (confirmed by culture); and previous use of 2 or more immunosuppressants. Statistical analysis was performed and multivariate analysis RESULTS: In our cohort, we had 213 patients in follow-up (March 2020) and during this period 29 (13.6%) patients with COVID-19 were evaluated. These 23 with diagnosis and supervised treatment in our service and 6 patients in external follow-up of the infectious condition. Overall death was 31% (9).The mean age of patients is 46 years (±15.66), being 51.8% male and 48.2% female. A multivariate analysis, only dialysis (HR 9.186 - CI 1.804-46.758 - p=0.008) and bronchopneumonia (HR 7.554 - CI 1.510-37.790 - p=0.014) are associated with a negative outcome. CONCLUSION: The lethality is high in this group of patients. Our data was shown that dialysis and bronchopneumonia are associated with a higher risk of death in this group of patients infected with COVID-19. We emphasize that the limitation of this work is mainly due to the small sample analyzed. We suggest more studies are necessary.
format Online
Article
Text
id pubmed-8988623
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-89886232022-04-11 Outcomes in Post Lung Transplant Patients Diagnosed with COVID 19 Pêgo-Fernandes, P. Reis, F. Pola Dos Santos, S. Fernandes, L.M. Abdalla, L.G. Aguiar, I.T. Campos, S.V. de Camargo, P. L. Bueno Costa, A.N. Carraro, R.M. Pires, J.P. Teixeira, R.O. J Heart Lung Transplant (976) PURPOSE: The manifestations and complications of SARS-CoV-2 infection in solid organ transplant are poorly known. Lung Transplant group is an immunocompromised group with a shock organ of COVID-19. For this, we analyze the possible risk factors associated with an unfavorable outcome METHODS: Retrospective study between the period march 2020 until june 2021. We analysed the database of Lung Transplant and medical records. It included all patients with a confirmed diagnosis of COVID-19 in our cohort with RT-PCR SARS-COV-2 or rapid test and chest computed tomography compatible. We analyzed demographic features and outcomes: sex; type of transplant (unilateral or bilateral); presence of chronic graft dysfunction; transplant time; confirmed prior rejections; history of SAH and/or DM; nosocomial transmission infection; report of fever and/or dyspnea; need for hospitalization and/or ICU; use of an O2 nasal catheter and/or mechanical ventilation; need of dyalisis; associated bronchopneumonia (confirmed by culture); and previous use of 2 or more immunosuppressants. Statistical analysis was performed and multivariate analysis RESULTS: In our cohort, we had 213 patients in follow-up (March 2020) and during this period 29 (13.6%) patients with COVID-19 were evaluated. These 23 with diagnosis and supervised treatment in our service and 6 patients in external follow-up of the infectious condition. Overall death was 31% (9).The mean age of patients is 46 years (±15.66), being 51.8% male and 48.2% female. A multivariate analysis, only dialysis (HR 9.186 - CI 1.804-46.758 - p=0.008) and bronchopneumonia (HR 7.554 - CI 1.510-37.790 - p=0.014) are associated with a negative outcome. CONCLUSION: The lethality is high in this group of patients. Our data was shown that dialysis and bronchopneumonia are associated with a higher risk of death in this group of patients infected with COVID-19. We emphasize that the limitation of this work is mainly due to the small sample analyzed. We suggest more studies are necessary. Published by Elsevier Inc. 2022-04 2022-04-07 /pmc/articles/PMC8988623/ http://dx.doi.org/10.1016/j.healun.2022.01.1555 Text en Copyright © 2022 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle (976)
Pêgo-Fernandes, P.
Reis, F. Pola Dos
Santos, S.
Fernandes, L.M.
Abdalla, L.G.
Aguiar, I.T.
Campos, S.V.
de Camargo, P. L. Bueno
Costa, A.N.
Carraro, R.M.
Pires, J.P.
Teixeira, R.O.
Outcomes in Post Lung Transplant Patients Diagnosed with COVID 19
title Outcomes in Post Lung Transplant Patients Diagnosed with COVID 19
title_full Outcomes in Post Lung Transplant Patients Diagnosed with COVID 19
title_fullStr Outcomes in Post Lung Transplant Patients Diagnosed with COVID 19
title_full_unstemmed Outcomes in Post Lung Transplant Patients Diagnosed with COVID 19
title_short Outcomes in Post Lung Transplant Patients Diagnosed with COVID 19
title_sort outcomes in post lung transplant patients diagnosed with covid 19
topic (976)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988623/
http://dx.doi.org/10.1016/j.healun.2022.01.1555
work_keys_str_mv AT pegofernandesp outcomesinpostlungtransplantpatientsdiagnosedwithcovid19
AT reisfpolados outcomesinpostlungtransplantpatientsdiagnosedwithcovid19
AT santoss outcomesinpostlungtransplantpatientsdiagnosedwithcovid19
AT fernandeslm outcomesinpostlungtransplantpatientsdiagnosedwithcovid19
AT abdallalg outcomesinpostlungtransplantpatientsdiagnosedwithcovid19
AT aguiarit outcomesinpostlungtransplantpatientsdiagnosedwithcovid19
AT campossv outcomesinpostlungtransplantpatientsdiagnosedwithcovid19
AT decamargoplbueno outcomesinpostlungtransplantpatientsdiagnosedwithcovid19
AT costaan outcomesinpostlungtransplantpatientsdiagnosedwithcovid19
AT carrarorm outcomesinpostlungtransplantpatientsdiagnosedwithcovid19
AT piresjp outcomesinpostlungtransplantpatientsdiagnosedwithcovid19
AT teixeiraro outcomesinpostlungtransplantpatientsdiagnosedwithcovid19